In 2014, Mary Hinz, MD, et al, published a paper that hypothesized that carbidopa depleted the body of vitamin B6 and that this decrease in B6 levels led to progressive neurodegeneration in patients with Parkinson’s disease. Two recent papers provide additional evidence that seems to support that assertion.
I’ve had several clients inquire about the amount of carbohydrates in the Mucuna powder that we use and whether that will affect their ability to follow a ketogenic diet and stay in ketosis, so I thought this an opportune time to address this issue in a post.
When working with people that have symptoms of a dopamine relative nutritional deficiency (i.e., those that are following a dopamine dominant protocol), elevated homocysteine is not an uncommon finding. However, determining the reason for this abnormal finding holds the key to resolving it.
Over the past two decades, we’ve worked with thousands of people that have relative nutritional deficiencies that exhibit symptoms similar to many diseases. I’ve often been asked for testimonials, so I thought I’d start sharing some of those – here’s the first from a woman that had been diagnosed with Parkinson’s Disease.(more…)
Adequate vitamin B6 levels are absolutely essential for proper neurotransmitter production and function. This is especially true if someone has previously taken a medication or substance that binds irreversibly with B6, such as carbidopa. Thus vitamin B6 supplementation is often needed to address B6 deficiency or insufficiency.(more…)
While someone is undergoing amino acid therapy for a relative nutritional deficiency that exhibits symptoms similar to a disease – such as depression, migraines or Parkinson’s Disease – they may find they have a loss of appetite and unwanted weight loss. This can be concerning; luckily, it can also be corrected.(more…)